Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allyson Parry

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The Lancet. Neurology|February 21, 2006
MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up studyTijmen Korteweg, Mar Tintoré, Bernard Uitdehaag, et al.
Journal of Neuro-Oncology|November 1, 2016
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohortKatrina A Morris, John F Golding, Claire Blesing, et al.
Archives of Disease in Childhood|March 15, 2018
Diagnosis of sporadic neurofibromatosis type 2 in the paediatric populationGeetha Anand, Grace Vasallo, Maria Spanou, et al.
Journal of Medical Genetics|August 16, 2015
Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patientsAdam Hexter, Adrian Jones, Harry Joe, et al.
Neurosurgery|October 4, 2017
Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated PatientAndrew T King, Scott A Rutherford, Charlotte Hammerbeck-Ward, et al.
Journal of Medical Genetics|June 26, 2024
<i>NF2</i>-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological studyClaire Forde, Miriam J Smith, George J Burghel, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 8, 2018
Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testingD Gareth Evans, Andrew T King, Naomi L Bowers, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|October 19, 2013
English consensus protocol evaluating candidacy for auditory brainstem and cochlear implantation in neurofibromatosis type 2James R Tysome, Patrick R Axon, Neil P Donnelly, et al.
Neuro-Oncology Advances|April 13, 2023
Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progressionD Gareth Evans, Dorothy Halliday, Rupert Obholzer, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 6, 2019
Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencingD Gareth Evans, Claire L Hartley, Philip T Smith, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The Lancet. Neurology|February 21, 2006
MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up studyTijmen Korteweg, Mar Tintoré, Bernard Uitdehaag, et al.
Journal of Neuro-Oncology|November 1, 2016
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohortKatrina A Morris, John F Golding, Claire Blesing, et al.
Archives of Disease in Childhood|March 15, 2018
Diagnosis of sporadic neurofibromatosis type 2 in the paediatric populationGeetha Anand, Grace Vasallo, Maria Spanou, et al.
Journal of Medical Genetics|August 16, 2015
Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patientsAdam Hexter, Adrian Jones, Harry Joe, et al.
Neurosurgery|October 4, 2017
Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated PatientAndrew T King, Scott A Rutherford, Charlotte Hammerbeck-Ward, et al.
Journal of Medical Genetics|June 26, 2024
<i>NF2</i>-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological studyClaire Forde, Miriam J Smith, George J Burghel, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 8, 2018
Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testingD Gareth Evans, Andrew T King, Naomi L Bowers, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|October 19, 2013
English consensus protocol evaluating candidacy for auditory brainstem and cochlear implantation in neurofibromatosis type 2James R Tysome, Patrick R Axon, Neil P Donnelly, et al.
Neuro-Oncology Advances|April 13, 2023
Radiation treatment of benign tumors in NF2-related-schwannomatosis: A national study of 266 irradiated patients showing a significant increase in malignancy/malignant progressionD Gareth Evans, Dorothy Halliday, Rupert Obholzer, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 6, 2019
Incidence of mosaicism in 1055 de novo NF2 cases: much higher than previous estimates with high utility of next-generation sequencingD Gareth Evans, Claire L Hartley, Philip T Smith, et al.
Pageof 3